Stay updated on Pembrolizumab and Mifepristone in Advanced Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Mifepristone in Advanced Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Mifepristone in Advanced Breast Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe study status is now Terminated, side effect 'rash' has been added to the adverse events, and completion/enrollment dates have been updated.SummaryDifference0.7%

- Check24 days agoChange DetectedLocations section added with Illinois as a location; Illinois Locations and HHS Vulnerability Disclosure removed, and the page revision updated to v3.3.3.SummaryDifference0.2%

- Check45 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check52 days agoChange DetectedThe warning banner about potential delays due to government funding has been removed from the page. This does not affect the study data, enrollment criteria, or results presented. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check75 days agoChange DetectedNo substantive changes detected to core study information (eligibility criteria, endpoints, or trial status); observed differences appear to be minor UI rendering variations between screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check96 days agoChange DetectedMajor update: new operating-status notice and a newer revision/version tag; older dates and revision removed.SummaryDifference4%

Stay in the know with updates to Pembrolizumab and Mifepristone in Advanced Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Mifepristone in Advanced Breast Cancer Clinical Trial page.